Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shanu Modi

Showing results (11-20 of 114) with videos related to

Pageof 12
Sort By:
The New England Journal of Medicine|September 21, 2022
Trastuzumab Deruxtecan in HER2-Low Breast Cancer. ReplyShanu Modi, Dhiraj Gambhire, David Cameron
Nature Reviews. Clinical Oncology|August 2, 2024
Author Correction: Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectivesAntonio Marra, Sarat Chandarlapaty, Shanu Modi
Discovery Medicine|February 21, 2016
Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directionsLaura Spring, Aditya Bardia, Shanu Modi
Nature Reviews. Clinical Oncology|January 9, 2024
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectivesAntonio Marra, Sarat Chandarlapaty, Shanu Modi
Breast Cancer Research : BCR|August 12, 2021
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directionsEmanuela Ferraro, Joshua Z Drago, Shanu Modi
Nature Reviews. Clinical Oncology|February 9, 2021
Unlocking the potential of antibody-drug conjugates for cancer therapyJoshua Z Drago, Shanu Modi, Sarat Chandarlapaty
Biochimica Et Biophysica Acta|November 9, 2011
Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancersKomal Jhaveri, Tony Taldone, Shanu Modi, et al.
Expert Opinion on Drug Discovery|March 9, 2012
Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatmentHardik J Patel, Shanu Modi, Gabriela Chiosis, et al.
Cancer Treatment Reviews|July 23, 2022
Beyond HER2: Targeting the ErbB receptor family in breast cancerJoshua Z Drago, Emanuela Ferraro, Nour Abuhadra, et al.
CNS Oncology|June 8, 2022
Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecanNelson S Moss, Umberto Tosi, Bianca D Santomasso, et al.
Pageof 12

Showing results (11-20 of 114) with videos related to

Sort By:
Pageof 12
The New England Journal of Medicine|September 21, 2022
Trastuzumab Deruxtecan in HER2-Low Breast Cancer. ReplyShanu Modi, Dhiraj Gambhire, David Cameron
Nature Reviews. Clinical Oncology|August 2, 2024
Author Correction: Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectivesAntonio Marra, Sarat Chandarlapaty, Shanu Modi
Discovery Medicine|February 21, 2016
Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directionsLaura Spring, Aditya Bardia, Shanu Modi
Nature Reviews. Clinical Oncology|January 9, 2024
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectivesAntonio Marra, Sarat Chandarlapaty, Shanu Modi
Breast Cancer Research : BCR|August 12, 2021
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directionsEmanuela Ferraro, Joshua Z Drago, Shanu Modi
Nature Reviews. Clinical Oncology|February 9, 2021
Unlocking the potential of antibody-drug conjugates for cancer therapyJoshua Z Drago, Shanu Modi, Sarat Chandarlapaty
Biochimica Et Biophysica Acta|November 9, 2011
Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancersKomal Jhaveri, Tony Taldone, Shanu Modi, et al.
Expert Opinion on Drug Discovery|March 9, 2012
Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatmentHardik J Patel, Shanu Modi, Gabriela Chiosis, et al.
Cancer Treatment Reviews|July 23, 2022
Beyond HER2: Targeting the ErbB receptor family in breast cancerJoshua Z Drago, Emanuela Ferraro, Nour Abuhadra, et al.
CNS Oncology|June 8, 2022
Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecanNelson S Moss, Umberto Tosi, Bianca D Santomasso, et al.
Pageof 12